Japanese lab buys 4-tesla scanner
Varian Associates of Palo Alto, CA, has sold the most powerfulwhole-body MRI scanner ever to be acquired by a Japanese laboratory. A Varian 4-tesla scanner will be installed this month at theInstitute of Physical and Chemical Research (RIKEN) in Wako
Varian Associates of Palo Alto, CA, has sold the most powerfulwhole-body MRI scanner ever to be acquired by a Japanese laboratory.
A Varian 4-tesla scanner will be installed this month at theInstitute of Physical and Chemical Research (RIKEN) in Wako City,Japan. It will be operated under the direction of Dr. Keiji Tanaka,head of RIKEN's neural information processing laboratory, to studybrain functions, such as recognition, memory, and motor programming.
The $4 million system consists of Varian's Unity Inova spectrometerand a magnet and gradient coils supplied by Siemens Medical Systems.It is the second 4-tesla scanner built by Varian since the companyreentered the ultra-high-field MRI manufacturing sector in 1995(SCAN 3/27/96). The other system was installed in Canada in Marchat Robarts Research Institute in London, Ontario.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
